- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03577691
Efficacy of a Decision Aid for Hydroxyurea in Sickle Cell Disease
Efficacy of a Decision Aid for Hydroxyurea(HU) in Sickle Cell Disease(SCD)
Study Overview
Status
Conditions
Detailed Description
Hydroxyurea (HU) has been demonstrated to be efficacious in reducing complications such as vasocclusive pain crises and acute chest syndrome in children and adults with Sickle Cell Disease (SCD) and in improving survival in adults. It is also the only disease-modifying therapy and the only drug approved by the FDA for use in patients with SCD. However significant barriers remain in prescription and utilization of HU. Some of the barriers are under prescription and when prescribed, underutilization by patients. The majority of the reasons for underutilization by patients being fear of cancer or other side effects, concern about lack of efficacy, and unwillingness to take the medicine or come to clinic or pharmacy.
Decision aids are designed to help patients improve their knowledge of the options, achieve a more accurate perception of risk and benefits of treatment, participate actively in decision making, and make choices more in keeping with their values and preferences. Decision aids have been shown to be effective in providing greater knowledge; lower decisional conflict among the subjects. The web based decision aid is also likely to serve as a tool for clarification of patient values to themselves and to their healthcare providers. The web based decision aid, sickleoptions.org is a rather extensive and detailed website with information regarding sickle cell disease(SCD) complications and standard of care monitoring and management as well as the treatment options of hydroxyurea, Endari, chronic blood transfusion, and bone marrow transplant. It is necessary to assure user ability to navigate all of the elements of the site. The study wants to determine the efficacy of training for a web based Decision Aid for Hydroxyurea(HU) usage among subjects with Sickle Cell Disease(SCD) that are randomized to using a web based decision aid with training versus without training.
In the first phase of the study cognitive interviews will be conducted with 10-20 parents of patients with SCD or patients with SCD age > 18 years for development of training to navigate website. Interviews will be conducted in 5-subject iterative cycles to identify ease of usability and issues regarding navigation and usability to develop a training guide for website.
After consent, subjects will be asked to complete demographic questionnaires. Subjects will be randomized to either receive training or to not receive training to use the website. All subjects will be asked to spend about 30mts navigating the website after consent. Those who are randomized to receive training will be trained to use it during this time. Those who do not receive training will be asked to navigate through the site on their own. They may be randomized to complete 4 question surveys during this time. Not everyone will need to complete these surveys. This will take about 15 minutes. They will then be contacted each week for the next 3 weeks with a reminder to use the website. At week 4 they will complete 5 surveys over the phone. They may be randomized to complete a telephone interview. This interview will take about 30 to 45 minutes and will be audio recorded for transcription and analysis. Subjects will then be contacted every 3 months for 1 year to see if they made a decision about whether or not to start hydroxyurea for themselves (>18 yr-old subjects) or their child. These phone calls will take less than 5 minutes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta
-
Atlanta, Georgia, United States, 30303
- Grady Health System
-
Atlanta, Georgia, United States, 30303
- Hughes Spalding Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals with sickle cell disease ages 18 to 80 years, inclusive Or parents of children (ages 9 months to <18 years) whose child has not started Hydroxyurea
- Patients who have made a past decision to not obtain treatment with Hydroxyurea or who have not obtained treatment with Hydroxyurea in past 12 months. Or parents of children who have made a past decision to not obtain treatment with Hydroxyurea or who have not obtained treatment with Hydroxyurea in the past 12 months.
- Patients or parents of children who's doctor identifies the patient/child as someone who should be on Hydroxyurea
- All participants will be able to comprehend English
- Subjects will have access to the internet from iPad, smart phone, or personal computer
- For the cognitive interviews participants will not be eligible to consider hydroxyurea as a treatment option
Exclusion Criteria:
- Patient who has already made a decision to begin and has started Hydroxyurea. Or parent who has already made a decision for their child to begin and the child has started Hydroxyurea.
- Participated in prior Decision Aid study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Training for use of web based Decision Aid
Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website.
They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea.
Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
|
Subjects will be guided during a 30 minutes training session to use the website
Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid.
subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid.
subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
|
Placebo Comparator: No training for use of web based Decision Aid
Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access.
They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning.
Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment.
Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
|
Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid.
subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid.
subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
Subjects will not be guided during a 30 minutes training session to use the website
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Knowledge Survey score to estimate the impact of use of the Decision Aid with training versus without training in improving knowledge regarding HydroxyUrea for Sickle Cell Disease
Time Frame: Baseline and 4 week follow up
|
Subjects knowledge will be tested by using a knowledge Survey that was given at baseline and at 4 weeks follow up phone call.
It is a 27 True, False or Unsure questionnaire that tests subjects knowledge of understanding risk for severe lung disease (pulmonary hypertension).
This test is administered to both groups that are in turn randomized to to receive the pretest AND posttest or just the posttest surveys.
|
Baseline and 4 week follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in decisional conflict scale to estimate the impact of use of the Decision Aid with training versus without training aid on decisional conflict
Time Frame: Baseline and 4 week follow up
|
The decisional conflict scale (DCS) measures personal perceptions of: uncertainty in choosing options; modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making; and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice.
There are 16 questions with score value from 0=strongly agree to 4=strongly disagree.
Scores range from 0(no decisional conflict) to 100 (extremely high decisional conflict)
|
Baseline and 4 week follow up
|
Change in decision self efficacy scale to estimate the impact of use of the Decision Aid with training versus without training aid on decisional conflict
Time Frame: Baseline and 4 week follow up
|
The decision self efficacy scale measures self confidence or belief in one's abilities in decision making, including shared decision making.
There are 11 questions with score value from 0=not confident at all to 4=very confident.
Scores range from 0(extremely low self efficacy) to 100 (extremely high self efficacy)
|
Baseline and 4 week follow up
|
Change in Preparation for Decision Making Scale to estimate the impact of use of the Decision Aid with training versus without training aid on decisional conflict
Time Frame: Baseline and 4 week follow up
|
The 'Preparation for Decision Making' scale assesses a patient's perception of how useful a decision aid or other decision support intervention is in preparing the respondent to communicate with their practitioner at a consultation focused on making a health decision.There are 10 questions with score value from 0=not at all to 5=a great deal.
High scores indicate higher perceived level of preparation for decision making
|
Baseline and 4 week follow up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00101669
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Training for use of web based Decision Aid
-
National Taiwan University HospitalRecruitingInfertility, Female | Female InfertilityTaiwan
-
Agency for Healthcare Research and Quality (AHRQ)Completed
-
National Taipei University of Nursing and Health...RecruitingShared Decision Making | Vaginal Birth After CesareanTaiwan
-
Stanford UniversityNational Cancer Institute (NCI)Completed
-
University of Wisconsin, MadisonCompletedBreast Cancer | Knowledge, Attitudes, Practice
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Agency for Healthcare Research and Quality...Active, not recruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage 0United States, Guam, Puerto Rico
-
China Medical University HospitalRecruitingRenal Replacement Therapy | End-stage Renal Disease | Decision Aid | Decision-makingTaiwan
-
University of SaskatchewanSaskatchewan Health Research FoundationCompleted
-
Rhode Island HospitalAgency for Healthcare Research and Quality (AHRQ)Unknown
-
University of Texas at AustinWashington University School of Medicine; Ohio State UniversityCompletedStage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast CarcinomaUnited States